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Background: A study was undertaken to study the effect of 18F-fluorodeoxyglucose (FDG) positron
emission tomography (PET) on the diagnosis and management of clinically problematic patients with
suspected non-small cell lung cancer (NSCLC).
Methods: A prospective before-after study was performed in a cohort of all 164 patients (university/
community settings) referred for PET between August 1997 and July 1999. PET was restricted to cases
where non-invasive tests had failed to solve clinical problems. The impact on diagnostic understanding
and management was assessed using questionnaires (intended treatment without PET, actual treatment
choice after PET, post hoc clinical assessment).
Results: Diagnostic problems especially pertained to unclear radiological findings (n=112; 63%),
mediastinal staging (n=36; 20%), and distant staging issues (n=16; 9%). PET findings were validated
by reviewing medical records. PET had a positive influence on diagnostic understanding in 84%.
Improved diagnostic understanding solely based on PET was reported in 26%. According to referring
physicians, PET resulted in beneficial change of treatment in 50%. Cancelled surgery was the most fre-
quent change in treatment after PET (35%).
Conclusion: FDG PET applied as “add on” technology in patients with these clinical problems appears
to be a clinically useful tool, directly improving treatment choice in 25% of patients. The value of
increased confidence induced by PET scanning requires further evaluation.
Medical imaging technology is rapidly expanding andthe role of each modality is being redefined con-stantly. Positron emission tomography (PET) using
18F-fluorodeoxyglucose (FDG) has emerged as an accurate
imaging modality in patients with lung cancer.1–3 Potential
clinical indications include the differential diagnosis of
benign versus malignant disease, initial (preoperative)
staging, evaluation of suspected recurrences, and follow up
after treatment. The use of PET in clinical practice is based
predominantly on studies of technical performance and
diagnostic accuracy.4 5 To ensure the appropriate use of PET,
such studies should be followed by an analysis of the impact
of PET on management decisions, outcomes of care, and cost
effectiveness.
In the northwestern part of the Netherlands where this
study was performed, a single PET scanner serves 2.7 million
inhabitants with 50% of its time slots available for clinical
purposes. To restrict the use of PET to those patients who may
benefit most, a programme has been developed to evaluate
the clinical usefulness of PET, investigating the cost effective-
ness of performing PET on a routine basis in the preoperative
staging of non-small cell lung cancer (NSCLC)6 and its impact
as an “add on” technique in specific problem cases. To meas-
ure the clinical value of PET in the latter group, we performed
a prospective before-after study in a cohort of clinically prob-
lematic cases, typically after an extensive conventional work-
up. This study design was used during the early studies of
computed tomographic (CT) scanning by Wittenberg et al,7
and allows a systematic assessment of the impact of a test on
diagnostic understanding as well as on patient management
within the clinical context.8
METHODS
To be eligible for PET scanning, patients had to have suspected
or proven NSCLC with a diagnostic problem which, according
to the referring physician, could not be solved by conventional
methods alone and in which the PET result might affect
patient management. In an attempt to restrict PET scanning
to such cases, referrals were only accepted after discussion of
the case between the physician and the staff nuclear medicine
physician in charge at the Clinical PET Center of the VU Uni-
versity Medical Center. PET scanning therefore typically
followed an extensive conventional work-up. All patients rou-
tinely underwent laboratory tests, bronchoscopy, chest radio-
graphy and CT scanning extending from the neck to the upper
abdomen (including liver and adrenal glands). Additional
diagnostic tests were performed in cases with signs and
symptoms suggestive of distant metastatic disease. Patients
entered in randomised9 or response monitoring trials10 were
not included in the present report.
Assessment of clinical value
The impact of PET on diagnostic understanding and
treatment choice was investigated using three questionnaires
(fig 1). These questionnaires were completed by the referring
physician before PET scanning, shortly after PET scanning,
and about 6 months after PET scanning, respectively. In the
first questionnaire, information was requested regarding the
histological diagnosis (if known), a definition of the current
diagnostic problem, a differential diagnostic consideration,
the results of diagnostic tests already performed, and any
planned diagnostic tests. In addition, the referring physician
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was requested to outline the intended patient management
plan if PET scanning was not available. The second question-
naire requested information regarding the working diagnosis
and planned treatment after PET scanning in addition to any
diagnostic tests that had been ordered as a direct con-
sequence of the PET scan result. In the final questionnaire
the referring physician was requested to convey the final
diagnosis and to rate the overall usefulness of PET separately
in terms of diagnostic understanding and treatment choice
according to the method of Wittenberg et al.7 This method
involves using a 5 point ordinal scale (box 1), with higher
scores representing an increasing positive impact.
All questionnaires were checked for internal consistency
between the pre-PET intentional management (question-
naire 1) and post-PET actual management (questionnaire 3).
In the case of inconsistencies, the referring physicians
concerned were asked to review the cases in question and to
revise the overall clinical value rating accordingly and these
data were used in the analysis. In the case of PET negative—
that is, suspected benign—coin lesions, follow up was
extended beyond 6 months by examining the medical records
of these patients.
Management changes
Treatment (management) changes were considered “major” if
treatment changed from one modality to another—for exam-
ple, from medical to surgical/radiation/no treatment or vice
versa11—and “minor” if treatment changed within a
modality—for example, altered medical, surgical or radio-
therapy approach.
PET imaging
Whole body FDG PET scans were performed with a dedicated
PET scanner (ECAT EXACT HR+, CTI/Siemens). Emission
scans, typically extending from mid skull to mid femur, were
performed in 2D mode, approximately 60 minutes after intra-
venous injection of 370 MBq (10 mCi) FDG. Patients were
asked to fast for at least 6 hours before the PET study. Oral
intake of water was encouraged.
PET scans were corrected for decay, scatter, and random
data. Scans were reconstructed as 128 × 128 matrices using
filtered back projection with a Hanning filter (cut off 0.5
cycles/pixel) resulting in a transaxial spatial resolution of
7 mm at full width half maximum. If possible, CT scan data
were used for more precise anatomical localisation of PET
abnormalities suspected as being malignant.
Referring physicians were informed by telephone of the
result of the PET scan and advice to the next step. Clinicians
were urged to verify clinically decisive PET findings by
conventional means (histology, imaging, follow up) and to
ignore unconfirmed hot spots. PET findings were retrospec-
tively validated by examination of the medical records of the
patients. Histopathological and clinical follow up findings that
showed a benign or malignant course were considered as a
valid reference test.
Statistical analysis
Differences in diagnostic understanding or treatment choice
between the three indications were tested by means of a two
sided Kruskal-Wallis test. The Wilcoxon-Mann-Whitney test
was used to test differences between two samples. Changes in
Figure 1 Study protocol. *Suspected NSCLC, diagnostic problem insoluble by conventional imaging, potential impact on patient
management.
PET scan
Result
Advice
Questionnaire 1
Current diagnosis
Diagnostic problem
Result and planned diagnostic tests
Intended management plan
Questionnaire 2
Final diagnosis (if known)
Additional verification tests
Planned treatment
Preliminary guidelines* Candidate for PET?
(Telephone consultation)
Questionnaire 3
Final diagnosis
Diagnostic understanding
Therapy of choice
Evaluation
Stop
Yes
No
Treatment
Box 1 Questionnaire on evaluation of impact of PET
Diagnostic understanding (DU)
DU=1: PET confused my understanding of this patient’s
disease and led to investigations I would not otherwise have
done
DU=2: PET confused my understanding of this patient’s
disease but did not lead to any additional investigations
DU=3: PET had little or no effect on my understanding of this
patient’s disease
DU=4: PET provided information which substantially improved
my understanding of this patient’s disease
DU=5: My understanding of this patient’s disease depended
upon diagnostic information provided only by PET (unavail-
able from any other non-surgical procedure)
Treatment choice (TC)
TC=1: PET led me to choose treatment which in retrospect was
not in the best interests of the patient
TC=2: PET was of no influence in my choice of treatment
TC=3: PET did not alter my choice of treatment but did
increase my confidence in the choice
TC=4: PET contributed to a change in my chosen treatment
but other factors (other imaging tests, other diagnostic tests,
changes in patient status) were equally or more important
TC=5: PET was very important compared with other factors in
leading to a beneficial change in treatment
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treatment plans before and after PET were tested by the mar-
ginal homogeneity test.12
RESULTS
During a 23 month period 179 patients with suspected
NSCLC were referred for PET scanning. The referring
physicians included pulmonologists (76%), oncologists (7%),
internists (6%), radiotherapists (6%), neurologists (3%), and
surgeons (1%) from 21 different university and community
hospitals. Questionnaires were returned from 178 (99%) and
a fully completed set of questionnaires (all items answered)
was obtained for 136 (76%) patients. Specifically, question-
naire 1 was fully completed for 83% of the patients, question-
naire 2 for 92%, and questionnaire 3 for 98% of patients. Indi-
cations for PET could be subdivided into six groups: unclear
radiological abnormality (including solitary pulmonary nod-
ules and lung masses, n=112; 63%), staging of the mediasti-
num (n=36; 20%), distant staging issues (n=16; 9%),
response monitoring (n=5; 2.8%), suspected recurrence
(n=5; 2.8%), and unknown primary (n=5; 2.8%). The
present report focuses on the first three clinical indications.
In these 164 patients the clinical work-up before PET
included laboratory tests, chest radiography, CT scan of the
chest (including liver and adrenal glands), and
bronchoscopy.13 In patients with distant staging problems
(n=16) the work-up before PET consisted of bone scintigra-
phy and radiographic studies in the three patients with clini-
cal concerns about skeletal metastases; CT evaluation of the
abdomen typically preceded referrals with suspect adrenal
enlargement or liver lesions in which biopsy specimens were
not considered feasible or had been inconclusive. In two
patients in whom a chest CT scan had shown additional and
indeterminate pulmonary lesions, bronchoscopic examination
had been negative and it was not considered feasible to take
biopsy specimens. In five patients with potentially solitary
brain metastases, dissemination tests had included CT
scanning (brain, chest, liver and adrenal glands) and bone
scintigraphy. In general, the work-up of patients with unclear
radiological findings before PET scanning conformed to
national guidelines.13
The diagnostic problems concerning mediastinal staging
leading to referral for PET (instead of invasive mediastinal
staging) included former mediastinoscopy, thoracotomy or
radiotherapy, indeterminate invasive staging results, medical
inoperability, and “to determine the most appropriate surgical
approach”. After careful evaluation we were unable to identify
a specific reason for choosing PET scanning as opposed to
mediastinoscopy to determine mediastinal lymph node
involvement in 10 patients.
In 29 of the 179 patients the initially formulated
management plans (to be carried out if PET had not been
available) were not consistent with the final assessment of the
impact of PET. For example, the physician’s written plan
before PET was to perform a thoracotomy, and a thoracotomy
was indeed performed but treatment choice was rated as 5
(PET was very important compared with other factors leading
to a beneficial change in treatment). Such inconsistent
assessments were revised by the referring physicians (specifi-
cally with respect to questionnaire 3) and corrected in 28
cases.
Diagnostic understanding
The impact of PET on diagnostic understanding was analysed
for each clinical indication (table 1). Overall, PET was solely
responsible for improved diagnostic understanding (DU=5) in
26% (95% CI 19 to 33) of the patients and substantially
contributed to diagnostic understanding (DU=4) in 58% (95%
CI 50 to 65). The effect of the PET result on diagnostic under-
standing was confusing and led to additional tests (DU=1) in
3% (95% CI 1 to 6) and had no or little effect (DU=3) in 9%
(95% CI 5 to 15). The impact of PET on diagnostic
understanding was not significantly different for the three
clinical indications (p=0.45). There was no significant differ-
ence (p=0.85) in diagnostic understanding ratings between
PET scans indicating malignancy where the tumour was
finally proved to be malignant (true positives) and scans indi-
cating benign disease where the lesion proved to be benign
(true negatives). To evaluate the presence of a potential clini-
cal learning curve of incorporating PET scanning results, we
compared the diagnostic understanding rating of “early”
patients (the first five patients) referred by a particular physi-
cian to the ratings of later patients (the sixth and subsequent
patients). The ratings in later patients tended to be
significantly higher (p=0.0192).
Diagnostic accuracy
Of the patients referred to resolve unclear radiological
findings, 76 had a positive PET scan result which proved to be
true positive in 68 patients (89%). Thirty six patients had a
negative scan reading—that is, no focally enhanced FDG
uptake suspicious of malignancy—which proved to be correct
(true negative) in 34 patients (94%) either by “wait and see”
policy (n=32) or surgery (n=2). The mean duration of follow
up in these patients was 20 months (range 6–36). In two
patients the PET scans proved to be false negative. These false
negative cases included a patient with a pulmonary fibrous
tumour (the patient underwent a curative pneumonectomy)
and a patient with mantle cell lymphoma (diagnosed 1 year
after the PET scan). In one patient the indeterminate solitary
pulmonary nodule proved to be true positive at surgery but
PETwas found to havemissedmicrometastatic involvement of
mediastinal lymph nodes.
Of the patients referred for mediastinal staging, 24 had a
positive PET scan result of which 22 were proved to be true
positive as shown by pathology in 16 patients and by follow up
in six patients; one was found to be false positive (as shown by
pathology) and one patient was lost to follow up. Eleven
patients had negative scan results which were found to be true
negative in 10 patients (as shown by pathology in six patients
and by follow up in four: mean time from PET to last chest
radiograph or CT scan was 15 months, range 13–17). In one
patient the PET scan was found to be false negative (as shown
by pathology). In one patient the scan trajectory did not
include the mediastinum due to claustrophobia.
Of the patients referred because of distant staging issues, 10
were found to be true positive (as shown by pathology in six
patients, follow up in two, and radiology in two). Six patients
proved to have a true negative PET scan as shown by follow up
in five patients (mean time of follow up 6 months, range 6–6).
In one patient the PET result proved to be false negative (bone
metastases).
Table 1 Impact of PET on diagnostic understanding (DU) ratings (defined in box 1)
DU=1 DU=2 DU=3 DU=4 DU=5 Missing Total
Radiological abnormality 3 6 12 61 29 1 112
Mediastinal staging 1 1 1 21 11 1 36
Distant staging 0 0 2 10 2 2 16
Overall 4 7 15 92 42 4 164
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Management changes
In 162 of the 164 cases studied explicit provisional therapeutic
plans had been stated before PET. In 103 patients this involved
surgery. After PET, surgery was the treatment most commonly
abandoned (table 2). PET contributed to a decision to forego
surgical treatment in 36 patients (35%; 95% CI 26 to 45) in
whom it had been provisionally planned. Of the patients in
whom surgery was not the proposed treatment before PET
(n=59), seven patients subsequently underwent surgery. In
these patients the intended treatment had been observation in
four patients, chemotherapy in two patients, and radiotherapy
in one. There was a significant change in terms of the “impact”
of treatment for the patient, mainly towards a less aggressive
approach (surgery→chemotherapy/radiotherapy→observation;
p=0.0001). The impact of PET on treatment was divided into
major or minor changes as outlined previously. PET was
responsible for changes in choice of treatment that were major
in 55 patients (66%; 95% CI 55 to 76) and minor in 28 patients
(34%; 95% CI 24 to 45).
Post hoc evaluation of treatment choice
The impact of PET on treatment choice was analysed for each
scan indication (table 3). According to the attending
physician, PET was the most important factor leading to a
beneficial change of treatment (TC=5) in 45 of 159 patients
(28%; 95% CI 21 to 35) and contributed to such change (TC=
4) in 34 (21%; 95% CI 15 to 28).
Of the 134 cases in which the physician reported increased
diagnostic understanding, therapeutic plans remained un-
changed in 59 cases (44%). No significant differences in
changes of treatment choice for the three different indications
were found (p=0.65). Treatment choice ratings after PET
scanning indicating malignancy when the suspected lesion
was indeed found to be malignant were not different from
scans indicating a benign lesion found to be benign (p=0.27).
Like diagnostic understanding, the treatment choice ratings
were significantly higher for later patients than for early
patients (p=0.037).
DISCUSSION
A new test that appears to be more accurate than the standard
ones will generate a clinical demand, even if its effect on clini-
cal outcome measures is still unclear. With scarce technology
like PET, overconsumption may result precluding general
accessibility. Evidence-based guidelines for routine use are
therefore needed so that the available scanning capacity can
be adjusted to the expected demand. However, guidelines aim
at the average patient and may not be applicable in specific
situations. In this prospective multicentre before-after study
the reported clinical impact of FDG PET as an “add on” tech-
nology to solve diagnostic problems in patients with suspected
NSCLC was considerable. Clinical compliance with the PET
results was high, and PET was reported to have led to benefi-
cial management changes (TC >4) in 50% of the patients in
the three clinical situations investigated. In addition, a positive
influence on diagnostic understanding (DU >4) by PET was
observed in 84% of the patients. Put in a more conservative
way, PET proved to be the key diagnostic tool in one of every
four patients referred for PET (DU/TC=5).
Interestingly,we observed an increasing appreciation of PET
over time. Even though other explanations may also be valid,
individual consultation and feedback as done in our setting is
known to improve patient referral patterns.14
Interpretation of the classification of “important contribu-
tion” to treatment choice by PET (TC=4) is not straightfor-
ward. It is recognised that, in most clinical situations,
decisions are made on the basis of a number of factors. Patient
management depends on the preoperative assessment of the
probability of disease, which is a joint function of multiple
diagnostic indicators such as signs, symptoms and test results
together with the effectiveness of the invasive procedures that
follow them. This complicates the assessment of the contribu-
tion of a single test to a change in patient management. Even
though the phrasing of the “contributive” ratings (DU/TC=4)
may benefit from accentuation, such positive perceptions may
always contain a spectrum of clinical relevance which is diffi-
cult to translate into outcomemeasures. The assessment of the
true value of “contributive” rather than directly decisive PET
findings (TC=4 v TC=5) is therefore best done in a
randomised study design.
Some studies have recently addressed the clinical impact of
PET. The methodologies and patient spectra were variable, but
the reported management changes (65–70%15–17) are uni-
formly higher than those observed as a by-product in accuracy
studies (10–59%18 19). This underlines the fact that manage-
ment change is multifactorial and does not merely depend on
a single test (such as PET). Alternatively, “clinical value” stud-
ies may have overestimated the true clinical contribution of
Table 2 Treatment changes after PET
(TC=4/5, n=78)
Treatment change No. of patients
Surgery to:
Radiotherapy 6
Chemotherapy 11
Observation 18
Radiotherapy to:
Surgery 1
Chemotherapy 2
Observation 3
Chemotherapy to:
Surgery 2
Radiotherapy 0
Observation 2
Observation to:
Surgery 3
Radiotherapy 4
Chemotherapy 1
Minor changes within:
Surgery 14
Radiotherapy 9
Chemotherapy 2
Table 3 Impact of PET on patient management and its clinical assessment (treatment
choice (TC) ratings as defined in box 1)
TC=1 TC=2 TC=3 TC=4 TC=5 Missing Total
Radiological abnormality 1 16 42 21 30 2 112
Mediastinal staging 3 11 10 10 2 36
Distant staging 3 4 3 5 1 16
Overall 1 22 57 34 45 5 164
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PET. Firstly, the clinical impact of a new technology depends
on the quality of the previous clinical work-up; poorly
performed conventional staging before PET scanning would
overestimate its actual value. We therefore made an effort to
restrict PET referrals to cases in whom conventional investiga-
tions had been performed and had failed. As we have shown,
this was the case in most of the patients. Further, a retrospec-
tive analysis of the pre-PET work-up showed adherence to
internationally accepted guidelines in the majority of patients.
Secondly, whether a specific test contributed significantly is a
matter of judgement, and thus subject to disagreement, error
and imprecise measurement.8 This was, indeed, the case in our
study; inconsistencies were identified in 18% of the question-
naire responses. To strengthen the evidence of before-after
studies, independent reviewing of the data by experts has
been suggested. This has been shown to reduce the presumed
benefit of a new technology as assessed by this type of study
design.20 However, such findings may also reflect the
heterogeneity of daily clinical practice in which patients are
actually diagnosed and treated. Thirdly, unconscious bias of
the referring clinicians in favour of the new technology may
have affected the results. We cannot rule out the possibility
that this has occurred, but the opposite may also be true. Even
though the sample was not randomly chosen, we found no
such effect in the medical records of the cases in which a pro-
longed follow up was needed and the data were derived from
a broad spectrum of hospitals.
The questionnaires used do confirm a distinction between
the clinical impact of a test on diagnostic understanding,
patient management, and (retrospective) clinical assessment
of the appropriateness of these changes. The data clearly show
that the perceived benefit of PET scanning consists of altered
patient management but, to an even greater extent, of
increased diagnostic understanding or confidence in cases
where patient management was not altered. In their present
form the questionnaires do not allow estimation of the
amount of clinical uncertainty. In our opinion, studies such as
this may serve to estimate the relative merits of PET for differ-
ent indications within a specific clinical context. If PET fails to
show clinical impact, the presumed indication for PET may be
removed from the list, whereas promising results warrant fur-
ther investigation. Our data do not represent consecutive
patients presenting with a similar clinical problem and, as
such, our results cannot be extrapolated to imply the routine
use of PET in all patients with suspected NSCLC. Estimation of
the cost-benefit of such an application requires a direct com-
parison between patients subjected to PET and conventional
work-up. Such a study is currently onoing in the Netherlands.
In summary, controlled implementation of PET as a “last
resort” diagnostic modality improved patient management in
at least 25% of clinically problematic cases with suspected
NSCLC. The combination of preliminary guidelines, intensive
feedback, and prospective monitoring may promote the effec-
tive use of scarce technology.
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